Rose Report Podcast – March 2017
This article was originally published in The Rose Sheet
The Rose Sheet’s editorial team discusses key news and developments in the cosmetics and dietary supplement sectors over the past month, including industry efforts to tack cosmetics regulatory reform provisions onto pending US user-fee reauthorization legislation, and dietary supplement firms’ ongoing struggle to comply with Good Manufacturing Practices requirements to FDA’s satisfaction.
You may also be interested in...
The US FDA released five device-related close-out letters in March.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.